NATCO Pharma shares rose over 2% on Monday, October 19, after the company announced the launch of Carboplatin Injection, used in the treatment of ovarian carcinoma.
In an exchange filing, the company said it has launched Carboplatin Injection, a generic version of Paraplatin® in the US market
The company launched this injectable drug through its US subsidiary NATCO Pharma USA LLC.
The Hyderabad-based company also added that it is launching this product in manufacturing collaboration with Teyro Labs Pvt Ltd, based in Chennai.
Carboplatin Injection is prescribed for managing advanced ovarian carcinoma, encompassing both first-line combination chemotherapy and supportive care for recurring malignancy following previous chemotherapeutic interventions.
According to industry sales data, Carboplatin Injection generated projected revenues of $27.8 million within the United States for the twelve months concluding in June 2026.
Q1 Results
When we take a quick look at the company’s performance in Q1FY27, its profit numbers stood at ₹206.5 crore in the first quarter. This meant a decline of 57% from the previous year’s ₹480.7 crore.
Its topline figures also diminished, as revenue slumped by 44.7%. The revenue for the June quarter fell to ₹735.2 crore from ₹1,328.9 crore in the last fiscal.
The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) declined 67.3% in the first quarter. EBITDA dropped to ₹186.5 crore from ₹571 crore in the prior fiscal. Its margins also shrank sharply to 25.4% from 43% in the year-ago period.
Stocks Performance
The stock opened at ₹786.95 and has traded within an intraday high of ₹794.80. In the past 30 days, the stock has fallen close to 2%.
The stock is trading 35.32% below its 52-week high of ₹1,216.81. Furthermore, it’s now trading 1.03% above its 52-week low of ₹779.00. The stock has closed in the green in 5 out of the last 10 completed trading sessions.
Also Read: UltraTech Cement Q2 Results: Higher volumes lift profit 21%, but shares slip